Latest Period
Q4 2025
Security Snapshot
DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) Institutional Ownership
CUSIP: 25253X207
13F Institutional Holders and Ownership History from Q4 2018 to Q1 2026
Institutions Reporting
92
Shares (Excl. Options)
12,053,996
Price
$7.96
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Voting Common Shares, no par value
- Symbol
- DMAC on Nasdaq
- Shares outstanding
- 52,272,727
- Price per share
- $6.30
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 12,053,996
- Total reported value
- $95,986,433
- % of total 13F portfolios
- 0%
- Share change
- -796,042
- Value change
- -$5,768,433
- Number of holders
- 92
- Price from insider filings
- $6.30
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value is tracked under CUSIP 25253X207.
- 92 institutions reported positions in Q4 2025.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 92 to 14 between Q4 2025 and Q1 2026.
- Reported value moved from $95,986,433 to $2,297,844.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 92 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 25253X207?
CUSIP 25253X207 identifies DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 25253X207:
Significant Owners of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| TRILL AB | 17% | +13% | $70,252,906 | +$8,447,765 | 8,825,742 | +14% | TRILL AB | 31 Dec 2025 |
| TomEnterprise AB | 16% | $32,695,950 | 8,383,577 | TomEnterprise AB | 23 Jul 2025 | |||
| JACINTO RICHARD II | 9.6% | $34,067,114 | 4,958,823 | Richard Jacinto II | 30 Sep 2025 | |||
| COOPERMAN LEON G | 6.6% | +5% | $28,462,500 | +$1,486,972 | 3,450,000 | +5.5% | Cooperman Leon G. | 31 Dec 2025 |
As of 31 Dec 2025, 92 institutional investors reported holding 12,053,996 shares of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC). This represents 23% of the company’s total 52,272,727 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) together control 21% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| COOPERMAN LEON G | 3.9% | 2,020,000 | -38% | 0.53% | $16,079,200 |
| BlackRock, Inc. | 3.6% | 1,900,899 | +13% | 0% | $15,131,156 |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 1.7% | 875,000 | 0% | 14% | $6,965,000 |
| MILLENNIUM MANAGEMENT LLC | 1.5% | 768,560 | -35% | 0% | $6,117,738 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.5% | 764,255 | +7.4% | 0% | $6,084,946 |
| VANGUARD GROUP INC | 1.4% | 723,120 | +8.8% | 0% | $5,756,035 |
| STATE STREET CORP | 1.2% | 627,771 | +32% | 0% | $4,997,057 |
| MORGAN STANLEY | 1% | 547,610 | -5.5% | 0% | $4,358,976 |
| FIRST MANHATTAN CO. LLC. | 0.77% | 405,000 | -20% | 0.01% | $3,223,800 |
| Bleichroeder LP | 0.73% | 382,317 | 0% | 0.54% | $3,043,243 |
| NORTHERN TRUST CORP | 0.62% | 325,527 | -4.1% | 0% | $2,591,196 |
| OSAIC HOLDINGS, INC. | 0.47% | 246,972 | +35% | 0% | $1,965,893 |
| LPL Financial LLC | 0.38% | 197,150 | -3% | 0% | $1,569,314 |
| GOLDMAN SACHS GROUP INC | 0.25% | 129,388 | +67% | 0% | $1,029,928 |
| Bank of New York Mellon Corp | 0.23% | 120,977 | +75% | 0% | $962,973 |
| Nuveen, LLC | 0.21% | 111,028 | +49% | 0% | $883,783 |
| CITADEL ADVISORS LLC | 0.21% | 110,737 | +60% | 0% | $881,467 |
| WELLINGTON MANAGEMENT GROUP LLP | 0.2% | 103,704 | 0% | $825,484 | |
| MEMBERS WEALTH LLC | 0.19% | 101,382 | 0.54% | $864,282 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.19% | 96,880 | +4.8% | 0% | $771,165 |
| Kalehua Capital Management LLC | 0.18% | 95,359 | 0% | 0.77% | $759,058 |
| Informed Momentum Co LLC | 0.17% | 91,425 | 0.08% | $727,743 | |
| FRED ALGER MANAGEMENT, LLC | 0.16% | 83,137 | 0% | $661,771 | |
| MAGNOLIA CAPITAL ADVISORS LLC | 0.15% | 77,405 | +674% | 0.13% | $616,144 |
| Blue Trust, Inc. | 0.13% | 69,122 | 0% | 0.01% | $550,211 |
Institutional Holders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 344,127 | $2,297,844 | -$110,324 | $6.77 | 14 |
| 2025 Q4 | 12,053,996 | $95,986,433 | -$5,768,433 | $7.96 | 92 |
| 2025 Q3 | 12,754,591 | $82,807,935 | +$25,371,563 | $6.87 | 77 |
| 2025 Q2 | 8,764,697 | $34,183,334 | +$4,951,594 | $3.90 | 58 |
| 2025 Q1 | 7,514,092 | $28,477,666 | +$2,854,596 | $3.79 | 57 |
| 2024 Q4 | 6,729,012 | $36,539,618 | +$6,248,431 | $5.43 | 45 |
| 2024 Q3 | 5,580,411 | $23,326,555 | +$2,250,136 | $4.19 | 40 |
| 2024 Q2 | 5,062,392 | $14,934,296 | +$1,369,212 | $2.95 | 32 |
| 2024 Q1 | 4,598,019 | $12,730,274 | +$2,073,072 | $2.77 | 31 |
| 2023 Q4 | 3,840,738 | $10,907,609 | -$629,214 | $2.84 | 37 |
| 2023 Q3 | 4,250,465 | $10,966,479 | +$1,920,978 | $2.58 | 35 |
| 2023 Q2 | 3,490,534 | $15,080,277 | +$4,150,477 | $4.32 | 30 |
| 2023 Q1 | 2,565,385 | $3,924,875 | +$61,558 | $1.53 | 22 |
| 2022 Q4 | 2,524,139 | $3,989,530 | -$6,541 | $1.58 | 27 |
| 2022 Q3 | 2,527,104 | $3,132,035 | -$2,355,232 | $1.24 | 23 |
| 2022 Q2 | 3,668,922 | $7,411,731 | -$802,498 | $2.02 | 24 |
| 2022 Q1 | 4,006,054 | $10,017,522 | -$427,839 | $2.50 | 28 |
| 2021 Q4 | 3,993,298 | $14,891,858 | +$4,430,787 | $3.73 | 34 |
| 2021 Q3 | 2,804,345 | $11,247,922 | -$4,241,878 | $4.01 | 31 |
| 2021 Q2 | 3,783,974 | $16,902,446 | -$48,644,584 | $4.45 | 38 |
| 2021 Q1 | 5,694,347 | $88,119,211 | +$33,217,401 | $9.15 | 38 |
| 2020 Q4 | 5,983,974 | $60,607,941 | +$30,865 | $10.14 | 34 |
| 2020 Q3 | 6,707,026 | $28,383,192 | +$15,491,837 | $4.24 | 30 |
| 2020 Q2 | 3,034,327 | $21,027,519 | +$1,227,002 | $6.93 | 20 |
| 2020 Q1 | 2,928,881 | $8,241,240 | +$5,983,161 | $2.80 | 18 |
| 2019 Q4 | 806,746 | $3,914,130 | -$398,177 | $4.85 | 13 |
| 2019 Q3 | 956,852 | $1,976,000 | -$928,156 | $2.07 | 14 |
| 2019 Q2 | 1,283,324 | $6,365,000 | +$1,445,583 | $4.96 | 14 |
| 2019 Q1 | 1,013,152 | $4,601,000 | +$283,018 | $4.54 | 10 |
| 2018 Q4 | 1,032,562 | $3,003,000 | +$3,003,000 | $2.91 | 7 |